Labeled human-use handbook
Yunnan Baiyao Capsules for People
The green Jiaonang box is a traditional Chinese medicine capsule produced by Yunnan Baiyao Group. This handbook follows the package insert — oral amounts, the insurance pill, food cautions — and sets those claims next to human surgical RCTs in comparison tables. It is not a prescription and not veterinary advice.
Key takeaways
-
Labeled for people Green Jiaonang is the human capsule presentation — follow the insert and a physician.
-
Adult oral pattern Insert language is typically 1–2 capsules, four times daily, unless a clinician directs otherwise.
-
Pregnancy: do not use Listed contraindication. The red insurance pill is reserved for severe traumatic injury.
- Each capsule is 0.25 g. Adult labeled oral use is 1–2 capsules, four times daily, unless a physician directs otherwise.[6]
- Randomized hospital trials in jaw, neck-spine, and prostate surgery reported less measured intraoperative blood loss with short preoperative capsule courses.[2]
- Separate Chinese literature also studies ulcerative colitis (adjuvant), peptic-ulcer bleeding with PPI, and pooled uterine-bleed / ulcer subgroups — usually as add-on care, with bias caveats.[8][9][10]
- Pregnancy and known allergy are contraindications.
- The red insurance pill is for severe traumatic injury, not routine days.[1]
- Jiaonang is not an FDA-approved U.S. drug. Statements on this site have not been evaluated by the FDA.[7]
What Yunnan Baiyao Capsules are
Yellow-brown capsules
- Sixteen 0.25 g capsules per box
- Ordinary labeled oral use
- Physician may change the schedule
Red insurance pill
- One pill in its own foil pocket
- Insert: relatively severe trauma first
- Leave it in the foil unless directed
Same carton — two different roles. See the insurance-pill handbook for detail.
Yunnan Baiyao Capsules are the capsule presentation of a nationally protected Chinese herbal formula. Export cartons use the pinyin Jiaonang. The powder is yellow to light brown, aromatic, and slightly numbing. Yunnan Baiyao Group is the manufacturer.[1]
A retail box holds 16 capsules plus one red insurance pill. A 10-box order from this store therefore contains 160 capsules and 10 insurance pills. Human labeled patterns on the insert include traumatic injury, stagnated swelling, and selected bleeding presentations. Individual results vary.
Labeled oral use from the insert
Children’s fractions on the insert still need clinical direction. Pregnancy is a contraindication.
| Who | Typical labeled amount | Notes |
|---|---|---|
| Adults | 1–2 capsules, four times daily | 0.25 g per capsule. Follow the physician if different. |
| Children 6–12 years | One half of the adult amount | Only with clinical direction. |
| Children 2–5 years | One quarter of the adult amount | Only with clinical direction. Not for unsupervised pediatric use. |
| Pregnancy | Do not use | Listed contraindication on the carton. |
Traditional notes about taking the formula with warm water or, in some presentations, wine apply to labeled human use. They do not apply to dogs, cats, or horses. Swallow the capsule with water unless your clinician says to open it.
The red insurance pill
For severe traumatic injury the insert allows one insurance pill first. Light injuries and other listed patterns do not require it. Keep the red pill in the foil until a clinician says otherwise. A longer handbook is the insurance pill article.
Cautions and adverse reactions
Do not use Yunnan Baiyao Capsules in pregnancy or if you are allergic to the formula. The carton asks users to avoid broad beans, fish, and sour or cold foods for one day after taking it.
Marketing surveillance listed on the insert includes digestive discomfort, rash, and, rarely, more serious hypersensitivity. Stop and seek care if those appear. This product is not a substitute for stitches, imaging, or a transfusion.
How Yunnan Baiyao Capsules help people — literature comparison
The insert describes Jiaonang as a hemostatic Chinese medicine for people. Modern trials cover two layers: double-blind peri-operative capsule RCTs (jaw, cervical spine, TURP)[2][3][4], and disease-area work — ulcerative colitis as an adjuvant[8], peptic-ulcer bleeding with a PPI[10], plus a 2014 meta-analysis of Chinese hemorrhage and ulcer trials[9]. The tables below put those papers next to the label — what helped under clinicians, and what that does not authorize at home.
What human capsule papers actually checked — surgery
| Source | What kind of check | Who | What they measured | What happened | Takeaway |
|---|---|---|---|---|---|
| Tang et al., 2009 [2] | RCT · double-blind · placebo | 87 people · bimaxillary orthognathic surgery (Le Fort I + BSSRO) | Estimated intraoperative blood loss | Capsules for 3 days before surgery + hypotensive anesthesia: mean loss ~331 mL vs ~420 mL placebo. No allergic or thromboembolic events reported in the trial. | Less surgical blood loss |
| Pan et al., 2006 [3] | Multi-center RCT · double-blind · placebo | 197 people · cervical open-door laminoplasty | Intraoperative blood loss; postoperative drainage | Oral capsules (~500 mg peri-operative course, 5 days): mean intraoperative loss ~350 mL vs ~443 mL placebo. Postoperative drainage and adverse-event rates not clearly different. | Less intra-op bleeding |
| Li et al., 2007 [4] | Multi-center RCT · double-blind · placebo | 203 men · TURP for benign prostate enlargement | Intraoperative bleeding volume, bleeding index, bleeding intensity | 500 mg four times daily for 3 days before TURP: mean bleeding ~147 mL vs ~182 mL placebo. Differences larger when resected tissue weighed more than 20 g. | Less TURP bleeding |
| Package insert (Group) [1] | Labeled indication | People using sealed Jiaonang cartons | What the carton is approved to claim | Traditional labeled patterns include traumatic injury, stagnated swelling, and selected bleeding presentations. Adult oral use on many inserts: 1–2 capsules (0.25 g), four times daily, unless a clinician directs otherwise. Pregnancy is a contraindication. | Label: hemostasis / trauma |
| Pharmacology review (Front Pharmacol) [5] | Narrative / evidence review | Formula family across capsules, powder, and topicals | Hemostasis, anti-inflammation, analgesia mechanisms and clinical summaries | Reviews summarize how Yunnan Baiyao preparations are studied for bleeding and related endpoints. Useful background — not a substitute for reading any single RCT above. | Mechanism context |
| NMPA / FDA status [7] | Regulatory context | Jiaonang as a Chinese registered medicine | What “approved” means in which country | Registered Chinese medicine presentation under NMPA-related regulation. Not an FDA-approved U.S. drug. Retail pages are not prescribing information. | Not FDA-approved (US) |
Other disease areas — ulcerative colitis, GI bleed, uterine bleed, skin ulcer
| Source | What kind of check | Who | What they measured | What happened | Takeaway |
|---|---|---|---|---|---|
| Zhao et al., 2016 [8] | Open-label RCT · adjuvant | 221 people · active ulcerative colitis | Time to clinical remission (26-week follow-up) | Yunnan Baiyao added to standard UC care: median remission ~9 weeks vs ~13 weeks without it. Stronger signal in moderate–severe and more extensive disease subgroups. | UC adjunct · faster remission |
| Zhang et al., 2019 [10] | RCT · capsules + PPI vs PPI care | 100 people · bleeding peptic ulcer | Hemostasis time, transfusion, symptom scores, hospital stay, hemoglobin | Capsules plus proton-pump inhibitor: shorter reported bleeding-stop time, less transfusion, faster symptom relief and shorter stay vs PPI-based care alone. Adverse-event rates similar. | GI bleed adjunct to PPI |
| Yang et al., 2014 (meta) [9] | Systematic review · 55 Chinese RCTs | 5,150 people · hemorrhage or ulcer trials pooled | Clinical “response / improvement” rates | Pooled RR favored Yunnan Baiyao alone or plus routine drugs for several bleed/ulcer settings. Subgroups often cited: ulcerative colitis, uterine hemorrhage, skin ulcer. Authors stress heterogeneity and possible publication bias. | Pooled signal · bias caveats |
| Yang 2014 · UC subgroup [9] | Meta subgroup of Chinese RCTs | Ulcerative colitis arms inside the 2014 review | Clinical response vs routine antiulcer / anti-inflammatory care | Alone or plus sulfasalazine / mesalazine-class regimens, pooled response favored Yunnan Baiyao in UC subgroups (RR around 1.18–1.22). Many included trials were small and single-center. | Supports UC adjunct signal |
| Yang 2014 · uterine bleed [9] | Meta subgroup of Chinese RCTs | Uterine hemorrhage (e.g. post-abortion / surgical related arms) | Clinical hemostasis / improvement vs routine hemostatics | YNBY alone vs Vitamins C/K or gel foam: RR ~1.14. Plus routine hemostatics (e.g. norethindrone / leonurus regimens): RR ~1.27 in pooled Chinese trials. Not a pregnancy-safe product — pregnancy remains a carton contraindication. | Uterine bleed signal (China) |
| Yang 2014 · skin ulcer [9] | Meta subgroup | Bedsore / skin-ulcer arms | Wound response vs Vaseline-type local care | Pooled RR ~1.20 for local skin-ulcer trials. Many protocols use powder or topical application on the wound — that is not the same as swallowing Jiaonang capsules from this shop. | Often topical · not oral SKU |
| UC retention enema trials [9] | Chinese RCTs · rectal route | Ulcerative colitis (enema ± oral mesalazine) | Clinical / endoscopic scores | Several Chinese papers report better UC scores when Yunnan Baiyao is given as a retention enema (sometimes with other powders). That route is not the sealed oral capsule carton this handbook sells. | Different route — do not mix up |
Condition matrix — where disease evidence is strongest vs weakest
| Condition / setting | Best human evidence cited here | Honest takeaway |
|---|---|---|
| Ulcerative colitis (active) | Zhao 2016 open-label adjuvant RCT; Yang 2014 UC meta-subgroups; some enema trials (different route).[8][9] | May shorten remission as add-on to standard UC drugs — not a solo IBD cure. |
| Bleeding peptic ulcer | Zhang 2019 capsules + PPI RCT; Yang 2014 peptic-ulcer / upper-GI bleed subgroups (mixed).[10][9] | Adjunct to acid suppression and hospital GI care — not a replacement for endoscopy or PPI. |
| Uterine / gynecologic hemorrhage | Yang 2014 pooled Chinese RCTs (alone and plus routine hemostatics).[9] | Signal in Chinese hospital series; pregnancy remains a labeled contraindication — clinician only. |
| Upper GI / epistaxis bleed (pooled) | Yang 2014 hemorrhage meta with routine hemostatics; epistaxis subgroups small.[9] | Complementary signal with bias/heterogeneity warnings — not first-line ER care. |
| Skin ulcer / bedsore | Yang 2014 skin-ulcer subgroup; often local powder/paste protocols.[9] | Local wound use ≠ oral Jiaonang evidence. Do not treat capsule sales copy as bedsore proof. |
| Elective surgery blood loss | Tang 2009, Pan 2006, Li 2007 double-blind peri-operative capsule RCTs.[2][3][4] | Clearest modern capsule design: less measured intra-op blood loss under anesthesia teams. |
Labeled help vs what the RCTs measured
| What the insert / tradition points to | What published human work actually measured |
|---|---|
| Help stop or slow bleeding after trauma (classic hemostatic reputation on the insert) | RCTs measured sponge / suction blood loss inside planned operations — jaw surgery, neck spine surgery, and prostate resection — not street first-aid or ER hemorrhage. |
| Support recovery from traumatic swelling / stasis patterns listed on the carton | Surgical papers focused on milliliters lost during the case. They did not re-prove every traditional “swelling” claim as a modern outpatient endpoint. |
| Bleeding or ulcer patterns that Chinese hospitals also study (GI bleed, UC, uterine bleeding) | Later disease literature (UC adjuvant RCT, peptic-ulcer + PPI RCT, and a 2014 meta-analysis of Chinese trials) sits beside the label — often as add-on care, with bias and heterogeneity caveats. |
| Adult oral schedule (often 1–2 × 0.25 g capsules, up to four times daily) | Hospital protocols used short preoperative courses or clinician-supervised adjuvant schedules. Those are not a DIY chart for every GI or gynecologic bleed. |
| Red insurance pill for severe traumatic injury | The RCTs above studied the regular capsules (or pooled Yunnan Baiyao presentations). They are not insurance-pill trials. |
| Household kit for everyday cuts and nosebleeds | Published human work is peri-operative or disease-adjunct under clinicians. Minor home bleeding still needs basic first aid; heavy bleeding needs emergency care. |
Common hopes vs what we can honestly say
| What people often hope | What the evidence / label supports |
|---|---|
| It replaces stitches, imaging, a transfusion, or a PPI for ulcer bleeding | Surgical and GI papers sit inside hospital care. Peptic-ulcer work studied capsules with a proton-pump inhibitor — not instead of acid suppression or endoscopy.[10] |
| It cures ulcerative colitis on its own | Zhao 2016 tested Yunnan Baiyao as an adjuvant to mesalazine, steroids, or biologics and reported faster remission — open-label, not monotherapy.[8] |
| Any positive surgery or UC paper means I should self-dose before a dental visit or flare | Tang, Pan, Li, Zhao, and Zhang protocols were supervised courses. Copying them at home without a clinician is not what those papers authorize. |
| Meta-analysis of Chinese RCTs settles every bleed and ulcer claim | Yang 2014 pooled many small Chinese trials and still warned about heterogeneity, bias risk, and unstable results after dropping weaker studies.[9] |
| Human RCTs prove the same milligram plan for dogs or horses | Animal use is extra-label. Veterinary papers may cite human surgery as background; they do not transfer a human schedule automatically.[6] |
| It is an FDA-approved U.S. drug because Chinese hospitals studied it | Chinese hospital RCTs and NMPA registration do not equal FDA approval. Statements on this site have not been evaluated by the FDA.[7] |
Bottom line: the clearest modern capsule RCTs show less measured intraoperative blood loss in specific operations. Separate Chinese literature also reports adjunct benefit in ulcerative colitis and peptic-ulcer bleeding, plus pooled signals for uterine bleeding and some ulcer settings — often small trials with bias risk. None of that makes Jiaonang an FDA-approved U.S. drug, a solo IBD cure, or a reason to skip emergency care.
Those papers still sit inside labeled human medicine under clinician care. They do not make Jiaonang an FDA-approved U.S. drug, a solo IBD or ulcer cure, or a milligram plan for pets or racehorses.[6][7]
Storage
Keep capsules sealed, cool, and dry. Validity is 60 months from the date on the carton. Do not use damaged foil or boxes without batch information. Questions about the red pill: see the insurance pill article.
Browse every usage handbook from the usage directory.
References
- Yunnan Baiyao Group. Official corporate site and Jiaonang (capsules) product information / package insert.Manufacturer of authentic Jiaonang. Read the carton insert in your box as the primary labeled source for oral amounts, the insurance pill, food cautions, and contraindications.
- Tang ZL, Wang X, Yi B, Li ZL, Liang C, Wang XX. Effects of preoperative Yunnan Baiyao capsules on intraoperative blood loss in bimaxillary orthognathic surgery: a prospective, randomized, double-blind, placebo-controlled study. Int J Oral Maxillofac Surg. 2009;38(3):261–266.87 patients; capsules for 3 days before Le Fort I + BSSRO under hypotensive anesthesia. Mean blood loss ~331 mL vs ~420 mL placebo. Not a license for unsupervised home use.
- Pan S, Sun Y, Li F, et al. Effects of Yunnan Baiyao on peri-operative bleeding of patients undergoing cervical open-door laminoplasty: a multi-center randomized double-blind placebo-control trial. Natl Med J China. 2006;86(27):1888–1890.197 patients; oral Yunnan Baiyao capsules ~500 mg for 5 days peri-operatively. Intraoperative blood loss ~350 mL vs ~443 mL placebo; postoperative drainage not clearly different.
- Li NC, et al. The effect of Yunnan Baiyao on reduction of intra-operative bleeding of the patients undergoing transurethral resection of prostate. Natl Med J China. 2007;87(15):1017–1020.203 men for TURP; 500 mg four times daily for 3 days preoperatively. Intraoperative bleeding ~147 mL vs ~182 mL placebo; effect clearer when resected tissue >20 g.
- Li Y, et al. Research advances in pharmacology, safety, and clinical applications of Yunnan Baiyao. Front Pharmacol. / PMC review summarizing hemostasis and related pharmacology across presentations.Broad pharmacology and clinical-application review of the Yunnan Baiyao formula family. Context for how capsules sit next to powder and topical forms — not a single dosing trial.
- Ness SL, et al. AJVR 2017 — discussion of human surgical prophylaxis literature and labeled human oral amounts.Summarizes labeled 0.25–0.5 g up to four times daily in people, as context when veterinary papers cite human surgical work.
- National Medical Products Administration (China) — drug regulation context.Jiaonang is a registered Chinese medicine presentation. It is not an FDA-approved U.S. drug.
- Zhao WZ, Diao N, Gu YX, Zhu XT, Li MS. Efficacy of Yunnan Baiyao as an adjuvant treatment for active ulcerative colitis: an open-label randomized controlled study. J South Med Univ. 2016;36(9):1186–1191.221 people with active UC. Yunnan Baiyao as adjuvant to standard care: median remission 9 weeks vs 13 weeks control. Open-label — not a double-blind capsule monotherapy trial.
- Yang B, Xu ZQ, Zhang H, et al. The efficacy of Yunnan Baiyao on haemostasis and antiulcer: a systematic review and meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2014;7(3):461–482.55 Chinese RCTs (5,150 people). Pooled signals for hemorrhage and ulcer subgroups (including UC, uterine bleeding, skin ulcer). Authors flag heterogeneity, bias risk, and unstable sensitivity results.
- Zhang X, Chen HQ, You JF. Clinical study of Yunnan Baiyao capsules combined with a proton-pump inhibitor for bleeding peptic ulcer. J New Chin Med (Xin Zhong Yi). 2019;51(10):119–121.100 people with bleeding peptic ulcer. Capsules + PPI vs PPI-based care: shorter reported hemostasis time, less transfusion, shorter stay. Single-center Chinese RCT — adjunct to acid suppression, not a solo ulcer cure.
FAQ: Jiaonang for people
What is the labeled adult oral amount?
The insert describes 1–2 capsules (0.25 g each), four times daily, unless a clinician directs otherwise. That is labeled human use, not a veterinary table.[6]
Do human studies show Jiaonang helps with bleeding?
Several randomized hospital trials reported less measured intraoperative blood loss after short preoperative capsule courses in jaw surgery, cervical laminoplasty, and TURP.[2][3][4] That is supervised peri-operative evidence — not a DIY schedule for every cut or dental visit.
What about ulcerative colitis or stomach-ulcer bleeding?
An open-label RCT found faster UC remission when Yunnan Baiyao was added to standard care.[8] A Chinese RCT reported better hemostasis metrics when capsules were combined with a PPI for bleeding peptic ulcer.[10] A 2014 meta-analysis pooled many Chinese bleed/ulcer trials with bias caveats.[9] These are adjunct signals — not solo cures.
Who should not take Yunnan Baiyao Capsules?
Pregnancy and known allergy to the formula are contraindications on the carton. Children need a clinician. Stop and seek care if rash, breathing difficulty, or severe digestive symptoms appear.
When is the red insurance pill used?
The insert reserves it for severe traumatic injury. Light injuries and routine capsule schedules do not require it. Take it only with professional advice.
Can I take Jiaonang with wine?
Traditional insert language about warm water or wine is for labeled human use and is not for children, pregnancy, or animals. Ask a physician if alcohol is appropriate for you at all.
Is this the same product veterinarians mention for dogs or horses?
Often yes: the green Jiaonang box. Animal use is extra-label. Do not copy a pet or horse schedule onto a person, or the reverse.
Shop authentic Yunnan Baiyao Capsules
Same green Jiaonang boxes from five warehouses. Return to the usage directory if you still need the matching handbook.